Personalized Vaccine With SOC Chemo Followed by Nivo in Pancreatic Cancer

Phase Ib clinical trial using Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides (PEP) in order to stimulate/induce both innate and adaptive immunity by activating T-cells and Natural Killer (NK) cells, combined with standard of care (SOC) adjuvant chemotherapy, followed by nivolumab, an antibody against Programmed Cell Death 1 (PD-1), to maintain and boost the vaccine's effect in patients with non-metastatic resectable pancreatic adenocarcinoma

NCT Number	NCT04627246
Lead Sponsor	Centre Hospitalier Universitaire Vaudois
Conditions	Pancreatic Adenocarcinoma
Enrollment	14 participants
Start Date	2020-09-11
Primary Completion	2028-09 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-08